Active Metastatic Prostate Cancer Clinical Trials

Data from ClinicalTrials.gov · Privacy-First Design · No Account Required · No Health Data Stored

Why Consider a Metastatic Prostate Cancer Clinical Trial?

• Find Trials That Fit — Browse recruiting Metastatic Prostate Cancer trials pulled directly from ClinicalTrials.gov — updated continuously so you always see real, active studies.
• No Medical Jargon — Eligibility criteria are rewritten into plain yes-or-no questions. It's always okay to answer "not sure" — your doctor can help fill in the rest.
• See How Well You Match — Get a clear picture of how closely a trial fits your situation, so you know which ones are worth bringing to your oncologist.
• Ready for Your Appointment — Generate a printable or emailable summary for your next visit. A caregiver can send it to your doctor ahead of time.

How It Works

1. Share a Few Details — Enter your Metastatic Prostate Cancer type, stage, and location. No personal health information is required or stored.
2. Answer Yes-or-No Questions — We rewrite complex eligibility criteria into plain language. "Not sure" is always a valid answer.
3. Bring Results to Your Doctor — Get a printable summary with the NCT ID, match assessment, and questions to ask your oncologist.

Free · No account · Nothing you enter is stored

Metastatic Prostate Cancer Clinical Trial FAQ

What is mHSPC versus mCRPC, and does it matter for trial eligibility?

Metastatic hormone-sensitive prostate cancer (mHSPC) means the cancer has spread but still responds to testosterone-lowering therapy (ADT). Metastatic castration-resistant prostate cancer (mCRPC) means the cancer is no longer controlled by ADT. These are biologically different disease states, and trials typically enroll one or the other. Knowing which category you fall into is the first step in identifying the right trials.

Are there trials for metastatic prostate cancer based on BRCA or HRR gene mutations?

Yes. PARP inhibitors (olaparib, rucaparib, niraparib) are approved or in trials for mCRPC patients with BRCA1/2 or other homologous recombination repair (HRR) gene mutations (ATM, CDK12, PALB2, RAD51). Germline and somatic testing is now recommended for all metastatic prostate cancer patients. A positive HRR result can unlock multiple trial options.

How does lutetium-177 PSMA therapy work, and can I join a trial for it?

Lutetium-177 PSMA (Lu-177 PSMA-617, brand name Pluvicto) is an FDA-approved radioligand therapy for PSMA-positive mCRPC. It delivers targeted radiation directly to prostate cancer cells expressing PSMA. Clinical trials are now testing Lu-177 PSMA in earlier settings (mHSPC, earlier mCRPC lines), in combination with other agents, and next-generation radioligand constructs. A positive PSMA PET scan is typically required.

What is oligometastatic prostate cancer, and are there trials for it?

Oligometastatic prostate cancer refers to a limited number of metastatic lesions (often defined as ≤3 or ≤5 sites). Trials are testing metastasis-directed therapy (SBRT or surgery to metastatic sites) to determine whether treating all visible disease sites can delay the need for systemic therapy or prolong the response to ADT. If you have only a few metastases, ask your oncologist about oligometastatic trials.

Can I join a metastatic prostate cancer trial if I'm already on enzalutamide or abiraterone?

It depends on the trial. Some trials add an investigational drug on top of ongoing novel hormone therapy. Others require stopping enzalutamide or abiraterone before enrollment (particularly if testing competing AR-pathway agents). Some trials specifically target patients who became resistant to these drugs. Trialify's eligibility questionnaire will ask about your current regimen and duration of treatment.

Explore Other Cancer Trial Guides

• Prostate Cancer — Prostate cancer trials are exploring next-generation hormone therapies, PARP inhibitors, radiopharmaceuticals, and novel immunotherapy combinations — including options for castration-resistant disease.
• Bladder Cancer — Bladder cancer trials are evaluating checkpoint immunotherapy, enfortumab vedotin-based combinations, and FGFR inhibitors for both non-muscle-invasive and muscle-invasive disease.
• Kidney Cancer — Kidney cancer trials are evaluating immunotherapy combinations, HIF-2α inhibitors like belzutifan, and novel TKI regimens for clear cell and non-clear cell renal cell carcinoma.
• Colorectal Cancer — Colorectal cancer trials are evaluating immunotherapy for MSI-H tumors, KRAS and BRAF targeted therapies, and novel combinations for metastatic disease. Many trials enroll both colon and rectal cancer patients.